This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Twinrix Paediatric is indicated for use in non-immune infants, children and adolescents from one year up to and including 15 years who are at risk of both hepatitis-A and hepatitis-B infection.
Therapeutic Area (MeSH)
ATC Code
J07BC20
ATC Item
combinations
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| hepatitis A virus (inactivated) | N/A | 甲肝疫苗 |
| hepatitis B surface antigen | N/A | 乙型肝炎病毒表面抗原 |
EMA Name
Twinrix Paediatric
Medicine Name
Twinrix Paediatric
Aliases
N/ANo risk management plan link.